IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets January 13, 2025 Read More »
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer’s Agitation “CALMA” and Expands Recruitment Strategy January 8, 2025 Read More »
IGC Pharma Expands Clinical Research for IGC-AD1, Addressing Cognitive Impairment and Underlying Pathology in Alzheimer’s December 30, 2024 Read More »
IGC Pharma Announces Participation in BioPartnering @ JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025 December 20, 2024 Read More »
IGC Pharma Advances IGC-AD1 as a Potential Alzheimer’s Therapy Addressing Cognitive Impairment and Underlying Disease Pathology December 2, 2024 Read More »
IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer’s Treatment November 25, 2024 Read More »
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in its Alzheimer’s Pipeline November 14, 2024 Read More »
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies November 6, 2024 Read More »
IGC Pharma Announces Patient Enrollment at Toronto’s Baycrest in Phase 2 Trial Investigating IGC-AD1 October 17, 2024 Read More »
IGC Pharma Wins 2 Awards in Phase 1 of NIA’S AI PREPARE Challenge, Advancing Alzheimer’s Early Prediction Research October 17, 2024 Read More »
